Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...

Genomics, Inc. (NASDAQ:TXG – Get Free Report) has received a consensus recommendation of “Hold” from the seventeen analysts ...

Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by Morgan Stanley from $28.00 to $26.00 in a research ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...

Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...

UBS analyst Dan Leonard maintains 10x Genomics with a Neutral rating and has lowered the price target from $20 to $14. JP ...

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company reported ...

A Wednesday night earnings report left big questions about how the spending reductions would affect the company.

Stifel lowered the firm’s price target on 10x Genomics (TXG) to $18 from $21 and keeps a Buy rating on the shares. The funding environment ...